NEW YORK – Chinese precision oncology company Genetron Health said Wednesday that it is collaborating with Darui Biotechnology to support Darui's development of pathogenic microorganism detection products on its sequencer.
The detection kits will run on the Genetron S5 next-generation sequencer. Genetron will also help Darui apply for registration of its reagent kits with regulatory authorities, the company said.